大腸がん治療薬の市場規模、シェア、成長分析、薬剤クラス別、がんタイプ別、流通チャネル別、地域別 - 産業予測、2024年～2031年

大腸がん治療薬の世界市場規模は2022年に116億米ドルと評価され、2023年の121億7,000万米ドルから2031年には178億4,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは4.9%で成長する見通しです。

世界の大腸がん治療薬市場は、座りがちなライフスタイル、不健康な食事の選択、高齢化の進行などが主な原因となって、疾病の罹患率が憂慮すべきほど上昇していることに牽引されて力強い成長を遂げています。高度な診断およびスクリーニング技術の導入により早期発見が容易になり、タイムリーな治療介入が可能になった。さらに、標的療法、免疫療法、副作用を最小限に抑えながら治療効果を高め、患者の転帰を改善する併用療法など、がん治療における技術革新も市場を大きく後押ししています。しかし、情勢に課題がないわけではないです。先進的ながん治療に伴う高額な費用はヘルスケアシステムに大きな負担となり、地域によってアクセスに不公平が生じる可能性があります。さらに、薬剤耐性の出現は長期にわたる治療効果を複雑にし、患者の長期寛解達成に大きな障害をもたらします。また、規制上の障害や複雑な償還制度も障壁となっており、厳しい医薬品承認プロセスや様々な償還政策が、先進的治療へのアクセスを制限する可能性があります。このようなハードルにもかかわらず、米国の大腸がん治療薬市場は持続的な成長の態勢を整えており、今後の予測期間には安定した年間平均成長率（CAGR）を達成すると予想され、大腸がんとの闘いにおける革新的なソリューションへの継続的な需要を示しています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• ケーススタディ分析
• 規制情勢
• イノベーションマトリクス
• 主な投資の分析
• 主な成功要因
• 競合の程度

大腸がん治療薬市場：薬剤クラス別

• 市場概要
• 化学療法
• 免疫療法
• その他

大腸がん治療薬市場：がんタイプ別

• 市場概要
• 大腸腺がん
• 消化管カルチノイド腫瘍
• その他

大腸がん治療薬市場：流通チャネル

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

大腸がん治療薬市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Amgen, Inc.（US）
• Bayer AG（Germany）
• Bristol-Myers Squibb Company（US）
• Lilly（US）
• Merck & Co., Inc.（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Sanofi（France）
• Pfizer Inc.（US）
• Novartis AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（US）
• AstraZeneca PLC（UK）
• Gilead Sciences, Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）
• Ipsen Pharma（France）
• Sumitomo Pharma Co., Ltd.（Japan）
• Exelixis, Inc.（US）
• BeiGene, Ltd.（China）
• Oncolytics Biotech Inc.（Canada）
• NantKwest, Inc.（US）
• Eisai Co., Ltd.（Japan）
• Incyte Corporation（US）
• MacroGenics, Inc.（US）
• Halozyme Therapeutics, Inc.（US）

Global Colorectal Cancer Therapeutics Market size was valued at USD 11.6 billion in 2022 and is poised to grow from USD 12.17 billion in 2023 to USD 17.84 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031).

The global colorectal cancer therapeutics market is experiencing robust growth driven by an alarming rise in the incidence of the disease, largely due to sedentary lifestyles, unhealthy dietary choices, and an increasingly aging population. The implementation of advanced diagnostic and screening techniques has facilitated early detection, enabling timely therapeutic interventions. Additionally, the market is significantly bolstered by innovations in cancer treatment, including targeted therapies, immunotherapies, and combination approaches that enhance treatment efficacy and improve patient outcomes while minimizing side effects. However, the landscape is not without challenges; the high costs associated with advanced cancer therapies present a substantial burden on healthcare systems, leading to potential inequities in access across different regions. Furthermore, the emergence of drug resistance complicates treatment efficacy over time, posing significant hurdles in achieving long-term remission for patients. Regulatory obstacles and intricate reimbursement systems also pose barriers, as stringent drug approval processes and variable reimbursement policies can restrict the accessibility of advanced therapies. Despite these hurdles, the US colorectal cancer therapeutics market is poised for sustainable growth, anticipated to achieve a steady compound annual growth rate (CAGR) in the upcoming forecast period, signaling a continued demand for innovative solutions in the fight against colorectal cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Colorectal Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Colorectal Cancer Therapeutics Market Segmental Analysis

Global Colorectal Cancer Therapeutics Market is segmented by Drug Class, Cancer Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Chemotherapy, Immunotherapy, and Others. Based on Cancer Type, the market is segmented into Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is significantly driven by a surge in awareness campaigns and comprehensive screening programs aimed at fostering early detection and diagnosis of colorectal cancer. As public health initiatives emphasize the importance of timely intervention, patients are increasingly accessing screenings that facilitate early identification of cancer, leading to improved treatment outcomes. This heightened awareness not only empowers individuals to seek appropriate medical care but also elevates the demand for innovative and effective therapeutics, as healthcare providers focus on optimizing treatment strategies for patients diagnosed at earlier stages of the disease. Consequently, this growing emphasis on early detection is a critical market driver.

Restraints in the Global Colorectal Cancer Therapeutics Market

A significant market restraint for the global colorectal cancer therapeutics market is the phenomenon of drug resistance that colorectal cancer cells can develop over time. This resistance diminishes the effectiveness of existing treatments, resulting in treatment failures and disease progression, which ultimately hampers patient survival rates. The challenge of overcoming this resistance complicates treatment protocols and necessitates the continuous development of new therapies, contributing to increased research and development costs. As a result, healthcare providers and pharmaceutical companies may face reduced treatment options and higher financial burdens, which can limit market growth and patient access to effective colorectal cancer therapeutics.

Market Trends of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is witnessing a notable trend towards the rising popularity of combination therapies. These innovative treatment approaches, which integrate chemotherapy, targeted therapy, and immunotherapy, are being increasingly explored for their ability to enhance therapeutic efficacy. By leveraging the synergistic effects of multiple modalities, combination therapies can significantly improve response rates, effectively tackle drug resistance, and ultimately prolong survival rates among colorectal cancer patients. This trend reflects a shift in treatment paradigms, as healthcare providers and researchers aim for more personalized, effective solutions in managing colorectal cancer, positioning combination therapies as a cornerstone in future therapeutic strategies.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Colorectal Cancer Therapeutics Market by Drug Class

• Market Overview
• Chemotherapy
• Immunotherapy
• Others

Colorectal Cancer Therapeutics Market by Cancer Type

• Market Overview
• Colorectal Adenocarcinoma
• Gastrointestinal Carcinoid Tumors
• Others

Colorectal Cancer Therapeutics Market byDistribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Colorectal Cancer Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Amgen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncolytics Biotech Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Halozyme Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments